AIDSWEEKLY Plus; Monday, March 2, 2009
Staff Medical Writers

NewsRx -- According to a study from London, the United Kingdom, "This paper summarises tuberculosis (TB) research over almost 30 years in Karonga District, northern Malawi, an area typical of much of rural Africa. The dominant factor has been the human immunodeficiency virus (HIV), which arrived in the district about 1980, leading to an increase in TB incidence to a peak of approximately 65 smear-positive pulmonary cases per 100000 population in 2000."

"Tuberculin surveys indicate annual risks of Mycobacterium tuberculosis infection of approximately 1%; thus, most of the population is uninfected and at risk of primary infection and disease. Molecular epidemiological studies demonstrate that about two thirds of TB arises from recent infection, but recognisable recent contact is responsible for only about 10% of disease. By 2001, 57% of TB was directly attributable to HIV, implying that it would have declined were it not for HIV. HIV infection increases the risk of TB most among young adults, and greatly increases the risk of recurrence from new infection after treatment. Mortality rates in the HIV-Infected are high, but there is no association of HIV with drug resistance. Other risk factors with relatively smaller effects include age and sex, contact, several genetic polymorphisms and area. Neither one nor two doses of the bacille Calmette-Guerin (BCG) vaccine provides protection against adult pulmonary TB, despite protecting against leprosy. Skin test surveys, cohort studies and comparative immunological studies with the UK suggest that exposure to environmental mycobacteria provides some protection against TB and that BCG's failure is attributable partly to this widespread heterologous exposure masking effects of the vaccine. Drug resistance has remained constant (<10%) over more than 20 years. Immunotherapy with M. vaccae provided no benefits, but treatment of HIV-positive patients with cotrimoxazole reduced mortality. The Karonga programme illustrates the value of long-term population-based studies to investigate the natural history of TB and to influence TB control policy," wrote A.C. Crampin and colleagues, University of London (see also HIV/AIDS Co-Infection).

The researchers concluded: "Current studies focus on immunological markers of infection, disease and protection, and on elucidating the impact of antiretroviral treatment on TB incidence at population level."

Crampin and colleagues published their study in International Journal of Tuberculosis and Lung Disease (What has Karonga taught us? Tuberculosis studied over three decades Int J Tuberc Lung Dis. 2009 Feb;13(2):153-64.

For more information, contact A.C. Crampin, University of London, Keppel St., London WC1E 7HT, UK.

Publisher contact information for the International Journal of Tuberculosis and Lung Disease is: International Union Against Tuberculosis Lung Disease (I U a T L D), 68 Boulevard Saint-Michel, 75006 Paris, France.

Keywords: United Kingdom, London, HIV/AIDS Co-Infection, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Cutaneous Tuberculosis, Epidemiology, HIV, Human Immunodeficiency Virus Bacterial Infection, Immunization, Immunology, Infectious Disease, Lung Disease, Mycobacteria, Mycobacterium Tuberculosis, Sexually Transmitted Disease, Viral, Virology, University of London.

This article was prepared by AIDS Weekly editors from staff and other reports.

2009-03-02
AW090303

Copyright © 2009 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the Elton John AIDS Foundation UK, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.